JETEMA, Co., Ltd.

KOSDAQ:A216080 Stock Report

Market Cap: ₩261.6b

JETEMA Past Earnings Performance

Past criteria checks 2/6

There is insufficient data on JETEMA's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate12.3%
Return on equity28.0%
Net Margin31.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 23
JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Recent updates

JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 23
JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Is JETEMA, Co., Ltd.'s (KOSDAQ:216080) Shareholder Ownership Skewed Towards Insiders?

Feb 25
Is JETEMA, Co., Ltd.'s (KOSDAQ:216080) Shareholder Ownership Skewed Towards Insiders?

JETEMA (KOSDAQ:216080) Is Carrying A Fair Bit Of Debt

Jan 21
JETEMA (KOSDAQ:216080) Is Carrying A Fair Bit Of Debt

The JETEMA (KOSDAQ:216080) Share Price Has Gained 110%, So Why Not Pay It Some Attention?

Dec 17
The JETEMA (KOSDAQ:216080) Share Price Has Gained 110%, So Why Not Pay It Some Attention?

Revenue & Expenses Breakdown

How JETEMA makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A216080 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2464,68720,55117,73410,680
30 Jun 2463,87720,23315,77911,544
31 Mar 2462,55114,19614,81111,026
31 Dec 2358,71613,96613,24910,223
30 Sep 2357,603-21,99013,9228,782
30 Jun 2355,439-18,14413,7077,449
31 Dec 2245,9941,45511,9556,263

Quality Earnings: A216080 has high quality earnings.

Growing Profit Margin: A216080 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A216080's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A216080's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.

Earnings vs Industry: A216080 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.3%).


Return on Equity

High ROE: Whilst A216080's Return on Equity (28%) is high, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:02
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JETEMA, Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ja Yong KooDB Financial Investment Co. Ltd.
Hyun Jeong SonYuanta Securities Korea Co., Ltd.